Compare Canopy Growth Corp (CGC) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Five9 Inc — how do they compare? Canopy Growth Corp trades at $1.02 (market cap $430.60M), while Five9 Inc trades at $33.69 (market cap $2.33B). The key difference: Five9 Inc is far larger — about 5.4× Canopy Growth Corp's market cap, and Five9 Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | FIVN | |
|---|---|---|
Market Cap | $430.60M | $2.33B |
Sector | Health | Technology |
52-Week High | $1.92 | $34.48 |
52-Week Low | $0.86 | $13.61 |
Enterprise Value | $388.01M | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CGC trades at $1.01, up 1.0% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 fiscal 2027 revenue growth of 13% year-over-year, beating estimates, yet continues to post net losses. Recent news highlights expansion in European medical cannabis markets and cost-cutting efforts, while analyst consensus is mixed with 33% buy ratings.
Outlook remains speculative with high execution risk; improving cash flow trends and potential U.S. rescheduling offer upside, but persistent negative margins and debt concerns weigh on equity value. Investors should weigh growth prospects against profitability challenges in the volatile cannabis sector.
FIVN trades at $33.80, up 3.59% today, near its 52-week high of $34.58. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million, marking a significant improvement from prior losses. Recent management appointments and AI-driven subscription growth are positive catalysts.
The outlook is positive given earnings momentum and analyst support, but risks include high valuation multiples, ongoing legal scrutiny, and dependence on competitive AI adoption. With 61% of analysts rating it a Buy and a consensus target of $32.67, near-term upside appears limited, but execution on guidance could drive further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
